Skip to main navigation
Skip to content
Customer Service: 866-788-9007
PHYSICIAN LOGIN   |   CRF LOGIN   
ORDER TEST
Castle Biosciences, Inc.
  • Company
    • About Us
    • History
    • Executive Management
    • Board of Directors
    • Licenses
    • Careers
    • Contact Us
  • Products
    • Cutaneous Melanoma
    • DecisionDx-Melanoma
    • DecisionDx-CMSeq
    • Uveal Melanoma
    • DecisionDx-UM
    • DecisionDx-UMSeq
    • DecisionDx-PRAME
  • Research & Development
    • Our Approach
    • Tests in Development
    • Cutaneous Squamous Cell Carcinoma
    • Suspicious Pigmented Lesions
  • Investors
    • Overview
    • News & Events
      • Press Releases
      • Events & Presentations
    • Stock Information
      • Stock Quote & Chart
      • Historic Price Lookup
      • Investment Calculator
    • Financials & Filings
      • SEC Filings
    • Analyst Coverage
    • Corporate Governance
      • Documents & Charters
      • Board of Directors
      • Management
      • Committee Composition
    • Investor Resources
      • Annual Meeting
      • Investor FAQs
      • Investor Contact
      • Email Alerts
  • Scientific Publications
  • Resources
    • Healthcare Professionals
    • Login/Register
    • Order a Test
    • Reimbursement
    • Patients
    • Overview of our Tests
    • Frequently Asked Questions
    • Insurance Coverage
  • July 9, 2020  Second Systematic Review and Meta-Analysis Published Demonstrating DecisionDx-Melanoma as Independent Predictor of Recurrence, Distant Metastasis and Overall Survival in Cutaneous Melanoma

Biography

David Kabakoff, Ph.D.

Director
  • Member of the Nominating and Corporate Governance Committee
  • Chair of the Compensation Committee
Latest News
  • Second Systematic Review and Meta-Analysis Published Demonstrating DecisionDx-Melanoma as Independent Predictor of Recurrence, Distant Metastasis and Overall Survival in Cutaneous Melanoma July 9, 2020
  • Castle Biosciences Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares of Common Stock July 2, 2020
  • Castle Biosciences Announces Pricing of $74.0 Million Public Offering of Common Stock June 24, 2020
  • Castle Biosciences Announces Proposed Underwritten Public Offering of Common Stock June 22, 2020
  • Castle Biosciences Announces Change of Location of Annual Meeting of Stockholders to Be Held June 4, 2020 May 22, 2020

Site - Investor Tools

Print Page
Print Page
RSS Feeds
RSS Feeds
Email Alerts
Email Alerts
Investor Contact
Investor Contact
Search
Search
 

Connect with Us

Company

  • About Us
  • History
  • Leadership
    • Executive Management
    • Board of Directors
  • Licenses
  • Careers
  • Contact Us

Products

  • Cutaneous Melanoma
    • DecisionDx-Melanoma
    • DecisionDx-CMSeq
  • Uveal Melanoma
    • DecisionDx-UM
    • DecisionDx-UMSeq
    • DecisionDx-PRAME

Research & Development

  • Our Approach
  • Tests in Development
  • Cutaneous Squamous Cell Carcinoma
  • Suspicious Pigmented Lesions

Latest News & Publications

  • Press Releases
  • Scientific Publications
  • Email Alerts

Resources

  • Healthcare Professionals
    • Login/Register
    • Order A Test
    • Reimbursement
  • Patients
    • Overview of our Tests
    • Frequently Asked Questions
    • Insurance Coverage
Copyright © 2020 Castle Biosciences, Inc. | All Rights Reserved
  • Privacy Policy
  • Terms of Use
  • Contact Us
7ads6x98y